Latest Views & News

OptiBiotix Health – ‘commercial and scientific update’, remains a strong buy

By Tom Winnifrith and Steve Moore | Saturday 23 July 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


OptiBiotix Health (OPTI) has announced an update on recent scientific and commercial activities, emphasising it is “increasing the range of products, applications, and territories creating the potential to open larger market opportunities”.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Tuesday »

SNX

Synectics – a recovery Buy?

 

GetAFix

Malcolm Stacey is Moving House

Monday »

WG

Wood Group - a Buy (again)?

 

Bear

Video: Bubbles always implode